Head-To-Head Survey: CASI Pharmaceuticals (NASDAQ:CASI) versus Parnell Pharmaceuticals (OTCMKTS:PARNF)

Parnell Pharmaceuticals (OTCMKTS:PARNF) and CASI Pharmaceuticals (NASDAQ:CASI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Parnell Pharmaceuticals and CASI Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parnell Pharmaceuticals	0	0	0	0	0.00
CASI Pharmaceuticals	1	0	1	0	2.00

CASI Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Parnell Pharmaceuticals.

Insider & Institutional Ownership

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Parnell Pharmaceuticals and CASI Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parnell Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CASI Pharmaceuticals	$26.85 million	0.10	-$39.26 million	($3.01)	-0.07

Parnell Pharmaceuticals has higher earnings, but lower revenue than CASI Pharmaceuticals.

Profitability

This table compares Parnell Pharmaceuticals and CASI Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Parnell Pharmaceuticals	N/A	N/A	N/A
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Summary

CASI Pharmaceuticals beats Parnell Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About Parnell Pharmaceuticals

Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal – U.S., Production Animal – Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.